Brokerages Expect Incyte Co. (INCY) Will Announce Quarterly Sales of $413.16 Million

Brokerages predict that Incyte Co. (NASDAQ:INCY) will report $413.16 million in sales for the current quarter, according to Zacks. Twenty analysts have made estimates for Incyte’s earnings, with the highest sales estimate coming in at $486.65 million and the lowest estimate coming in at $374.55 million. Incyte posted sales of $326.50 million during the same quarter last year, which suggests a positive year over year growth rate of 26.5%. The firm is expected to issue its next quarterly earnings report before the market opens on Thursday, February 15th.

According to Zacks, analysts expect that Incyte will report full year sales of $413.16 million for the current fiscal year, with estimates ranging from $1.47 billion to $1.56 billion. For the next year, analysts anticipate that the company will report sales of $1.77 billion per share, with estimates ranging from $1.52 billion to $1.96 billion. Zacks’ sales averages are a mean average based on a survey of analysts that that provide coverage for Incyte.

Incyte (NASDAQ:INCY) last announced its quarterly earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.17 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.06 by $0.11. The firm had revenue of $381.50 million for the quarter, compared to the consensus estimate of $360.34 million. Incyte had a negative net margin of 10.90% and a negative return on equity of 12.91%. The company’s revenue for the quarter was up 41.6% on a year-over-year basis. During the same period in the prior year, the firm posted $0.19 earnings per share.

A number of equities research analysts recently weighed in on the stock. BidaskClub downgraded shares of Incyte from a “sell” rating to a “strong sell” rating in a research note on Tuesday, January 16th. BMO Capital Markets reaffirmed a “buy” rating and issued a $172.00 target price on shares of Incyte in a research note on Wednesday, January 3rd. Oppenheimer set a $120.00 target price on shares of Incyte and gave the company a “hold” rating in a research note on Tuesday, January 2nd. Goldman Sachs Group assumed coverage on shares of Incyte in a research note on Friday, October 6th. They issued a “buy” rating and a $160.00 target price on the stock. Finally, Royal Bank of Canada raised shares of Incyte from a “sector perform” rating to an “outperform” rating and set a $136.00 target price on the stock in a research note on Tuesday, January 2nd. Three investment analysts have rated the stock with a sell rating, six have given a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the stock. Incyte currently has a consensus rating of “Buy” and a consensus price target of $143.71.

In other news, Director Paul A. Friedman sold 28,507 shares of the firm’s stock in a transaction that occurred on Thursday, November 16th. The shares were sold at an average price of $105.24, for a total value of $3,000,076.68. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider David W. Gryska sold 3,915 shares of the firm’s stock in a transaction that occurred on Thursday, November 2nd. The stock was sold at an average price of $105.63, for a total transaction of $413,541.45. The disclosure for this sale can be found here. Insiders have sold 44,878 shares of company stock worth $4,636,494 over the last quarter. Company insiders own 17.70% of the company’s stock.

Several institutional investors have recently modified their holdings of the company. Nordea Investment Management AB grew its holdings in shares of Incyte by 0.8% in the second quarter. Nordea Investment Management AB now owns 8,179 shares of the biopharmaceutical company’s stock worth $1,030,000 after purchasing an additional 67 shares during the last quarter. Tower Research Capital LLC TRC grew its holdings in shares of Incyte by 13.8% in the second quarter. Tower Research Capital LLC TRC now owns 891 shares of the biopharmaceutical company’s stock worth $112,000 after purchasing an additional 108 shares during the last quarter. Ameritas Investment Partners Inc. grew its holdings in shares of Incyte by 1.9% in the second quarter. Ameritas Investment Partners Inc. now owns 7,571 shares of the biopharmaceutical company’s stock worth $953,000 after purchasing an additional 143 shares during the last quarter. AMP Capital Investors Ltd grew its holdings in shares of Incyte by 0.7% in the third quarter. AMP Capital Investors Ltd now owns 72,076 shares of the biopharmaceutical company’s stock worth $8,414,000 after purchasing an additional 500 shares during the last quarter. Finally, Hanseatic Management Services Inc. grew its holdings in shares of Incyte by 6.8% in the second quarter. Hanseatic Management Services Inc. now owns 7,924 shares of the biopharmaceutical company’s stock worth $998,000 after purchasing an additional 506 shares during the last quarter. Hedge funds and other institutional investors own 90.76% of the company’s stock.

Shares of Incyte (NASDAQ:INCY) traded up $1.24 on Thursday, reaching $93.16. 1,877,992 shares of the company were exchanged, compared to its average volume of 1,610,000. The stock has a market capitalization of $19,660.00, a P/E ratio of -116.45 and a beta of 0.74. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.82 and a quick ratio of 4.81. Incyte has a 1-year low of $88.81 and a 1-year high of $153.15.

COPYRIGHT VIOLATION WARNING: “Brokerages Expect Incyte Co. (INCY) Will Announce Quarterly Sales of $413.16 Million” was originally posted by Week Herald and is the property of of Week Herald. If you are reading this article on another domain, it was illegally copied and republished in violation of United States and international copyright law. The legal version of this article can be accessed at https://weekherald.com/2018/01/21/brokerages-expect-incyte-co-incy-will-announce-quarterly-sales-of-413-16-million.html.

Incyte Company Profile

Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib).

Get a free copy of the Zacks research report on Incyte (INCY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Incyte (NASDAQ:INCY)

Receive News & Ratings for Incyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply